Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0764 -0,0002 (-0,02%) Bitcoin EUR
59.629,94 +772,32 (+1,31%) CMC Crypto 200
1.335,84 +58,86 (+4,61%)
MiNK Therapeutics, Inc. (INKT)
Dopo ore:
| Chiusura precedente | 0,9694 |
| Aperto | 0,9900 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,9400 - 0,9900 |
| Intervallo di 52 settimane | 0,7500 - 3,3400 |
| Volume | |
| Media Volume | 101.306 |
| Capitalizzazione | 34,005M |
| Beta (5 anni mensile) | 0,12 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,6500 |
| Prossima data utili | 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,00 |
GlobeNewswireMiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797’s distinct mechanism of action in solid tumors. A poster will be presented
- GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences: Baird 2023 Global Healthcare Conferenc
- GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress - MiNK-215, a Novel FAP-CAR-iNKT Cell Therapy, Eliminated Tumors in NSCLC Models NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer
